FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE™ platform

Cancer Genetics

Volumn 204, Issue 11, 2011, Pages 589-595

  Mayer, Julie Ann ^a   Pham, Tam ^a   Wong, Karina L ^a   Scoggin, Jayne ^a   Sales, Edgar V ^a   Clarin, Trisky ^a   Pircher, Tony J ^a   Mikolajczyk, Stephen D ^a   Cotter, Philip D ^a   Bischoff, Farideh Z ^a  

^a Biocept Inc   (United States)

Author keywords

CTC; FISH; HER2; Microfluidic

Indexed keywords

CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; CD45 ANTIGEN; CREATINE KINASE; ERBB2 PROTEIN, HUMAN; PTPRC PROTEIN, HUMAN;

ADULT; AGED; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CIRCULATING TUMOR CELL; CONTROLLED STUDY; CROSS REACTION; DOWN REGULATION; FEASIBILITY STUDY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; METASTASIS; MICROFLUIDIC ANALYSIS; PREDICTIVE VALUE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; BLOOD; BREAST TUMOR; CELL SEPARATION; CHEMISTRY; COMPARATIVE STUDY; FEMALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; TUMOR EMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD45; BREAST NEOPLASMS; CELL SEPARATION; CREATINE KINASE; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MICROFLUIDIC ANALYTICAL TECHNIQUES; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; RECEPTOR, ERBB-2;

EID: 84857088316     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2011.10.011     Document Type: Article

References (32)

1. Lacroix M., Toillon R.A., Leclercq G. Stable "portrait" of breast tumors during progression: data from biology, pathology and genetics. Endocr Relat Cancer 2004, 11(3):497-522.
2. Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19(5):403-410.
3. Todd J.H., Dowle C., Williams M.R., et al. Confirmation of a prognostic index in primary breast cancer. Br J Cancer 1987, 56(4):489-492.
4. Pereira H., Pinder S.E., Sibbering D.M., et al. Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology 1995, 27(3):219-226.
5. Reis-Filho J.S., Tutt A.N. Triple negative tumours: a critical review. Histopathology 2008, 52(1):108-118.
6. Fehm T., Muller V., Aktas B., et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat 2010, 124(2):403-412.
7. Cristofanilli M., Budd G.T., Ellis M.J., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351(8):781-791.
8. Cristofanilli M., Hayes D.F., Budd G.T., et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005, 23(7):1420-1430.
9. Fehm T., Sagalowsky A., Clifford E., et al. Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res 2002, 8(7):2073-2084.
10. Scher H.I., Jia X., de Bono J.S., et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 2009, 10(3):233-239.
11. Nagrath S., Sequist L.V., Maheswaran S., et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007, 450(7173):1235-1239.
12. Hayes D.F., Cristofanilli M., Budd G.T., et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006, 12(14 Pt 1):4218-4224.
13. Paterlini-Brechot P., Benali N.L. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett 2007, 253(2):180-204.
14. Meng S., Tripathy D., Frenkel E.P., et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004, 10(24):8152-8162.
15. Allard W.J., Matera J., Miller M.C., et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004, 10(20):6897-6904.
16. Dickson MN, Tsinberg P, Tang Z, et al Efficient capture of circulating tumor cells with a novel immunocytochemical microfluidic device. Biomicrofluidics [In press].
17. Landis J.R., Koch G.G. The measurement of observer agreement for categorical data. Biometrics 1977, 33(1):159-174.
18. Polanski M., Anderson N.L. A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights 2007, 1:1-48.
19. Grushko T.A., Blackwood M.A., Schumm P.L., et al. Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res 2002, 62(5):1481-1488.
20. Punnoose E.A., Atwal S.K., Spoerke J.M., et al. Molecular biomarker analyses using circulating tumor cells. PLoS One 2010, 5(9):e12517.
21. Bieche I., Lidereau R. Genetic alterations in breast cancer. Genes Chromosomes Cancer 1995, 14(4):227-251.
22. Iglehart J.D., Kraus M.H., Langton B.C., Huper G., Kerns B.J., Marks J.R. Increased erbB-2 gene copies and expression in multiple stages of breast cancer. Cancer Res 1990, 50(20):6701-6707.
23. Lacroix H., Iglehart J.D., Skinner M.A., Kraus M.H. Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene 1989, 4(2):145-151.
24. Simon R., Nocito A., Hubscher T., et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001, 93(15):1141-1146.
25. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235(4785):177-182.
26. Sauter G., Lee J., Bartlett J.M., Slamon D.J., Press M.F. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009, 27(8):1323-1333.
27. Gancberg D., Di Leo A., Cardoso F., et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002, 13(7):1036-1043.
28. Guarneri V., Giovannelli S., Ficarra G., et al. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist 2008, 13(8):838-844.
29. Munzone E., Nole F., Goldhirsch A., et al. Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. Clin Breast Cancer 2010, 10(5):392-397.
30. Pestrin M., Bessi S., Galardi F., et al. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat 2009, 118(3):523-530.
31. Mikolajczyk S.D., Millar L.S., Tsinberg P., et al. Detection of EpCAM-negative and cytokeratin-negative circulating tumor cells in peripheral blood. J Oncol 2011, 2011:252361.
32. Flores L.M., Kindelberger D.W., Ligon A.H., et al. Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. Br J Cancer 2010, 102(10):1495-1502.